New Drugs Part 2, Pediatric Pharmacotherapeutics,, Chronic Kidney Disease (CKD) Treatment in Primary Care, Covid-19 Updates-

Course overview

At the completion of this activity, the participant will be able to New Drugs Part 2 1 Identify 10 20 new medications 2 Discuss the use, side effects, drug-drug interactions, and benefits of each of the medications. 3 Discuss updates related to labeling, indications, risks associated with various medications. Pediatric Pharmacotherapeutics: 4 Identify ways in which children are different than adults in terms of pharmacotherapeutics . 5 Discuss common pediatric prescribing errors. 6)Discuss strategies to prevent pediatric prescribing errors. 7 Identify medications with new pediatric approvals. CKD Treatment in Primary Care 8 Recognize CKD in patients with reduced kidney function, including in early stages of disease. 9 Implement screening for albuminuria in patients with diabetes in clinical practice to identify CKD as early as possible. 10 Describe therapy with evidence-based therapies, including newer agents, for patients with CKD when indicated. Covid19 Updates: Drug-Drug Interactions and The Impact on Patients with Covid and Other Chronic Conditions : 1. Identify disparity gaps in treatment, management, and drug interactions in outpatients with COVID19. 2. Assess and manage outpatients with COVID19 for drug interactions.3.Discuss the National COVID19 Treatment Guidelines for outpatients with COVID19.